Topotecan - GlaxoSmithKline
Alternative Names: Hycamptamine; Hycamtin; NK-211; Nogitecan; NSC 609699; SKF 104864; SKF S-104864-A; Topotecan HCl; Topotecan hydrochlorideLatest Information Update: 05 Nov 2023
At a glance
- Originator GlaxoSmithKline
- Developer GSK; Merck Pharmaceuticals UK; Nippon Kayaku; Novartis; SCRI Development Innovations
- Class Antineoplastics; Camptothecins; Small molecules
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Cervical cancer; Ovarian cancer; Small cell lung cancer
- Discontinued Brain metastases
Most Recent Events
- 23 Jun 2022 Novartis plans a phase I/II trial for Solid tumours (Combination therapy, Second-line therapy or greater) in August 2022 (NCT05429502)
- 24 Aug 2021 Novartis Pharmaceuticals terminates a phase Ib/II study in Small-cell lung cancer and Ovarian cancer (Second-line therapy or greater, Combination therapy) in USA (PO)(NCT02649673)
- 10 Jul 2019 Discontinued - Phase-III for Brain metastases (Metastatic disease) in Hungary, Poland, Russia, Canada, Slovakia, USA (PO)